Comparative Pharmacology
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus HYDRO RIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE versus HYDRO RIDE.
HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE vs HYDRO-RIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydralazine is a direct-acting arteriolar vasodilator that reduces peripheral vascular resistance via relaxation of vascular smooth muscle, possibly by interfering with calcium transport. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, and reducing plasma volume.
Thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water.
Initially one capsule (25 mg hydralazine/25 mg hydrochlorothiazide, or 50 mg hydralazine/50 mg hydrochlorothiazide) twice daily, increase as needed to a maximum of 200 mg hydralazine/200 mg hydrochlorothiazide daily.
Initiate at 12.5-25 mg orally once daily. Titrate to 50-100 mg once daily. Maximum 200 mg per day.
None Documented
None Documented
Hydralazine: 2-8 hours (terminal, prolonged in renal impairment; acetylator phenotype affects clearance; slow acetylators have 2-fold longer half-life). Hydrochlorothiazide: 6-15 hours (terminal, prolonged in renal impairment; clinically relevant for once-daily dosing).
Terminal half-life 4-6 hours (prolonged in renal impairment).
Hydralazine: 90% renal (primarily as metabolites, 10-15% unchanged); Hydrochlorothiazide: >95% renal (unchanged). Biliary/fecal: negligible for both.
Primarily renal (50% unchanged; remainder as glucuronide conjugate); biliary/fecal <10%.
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic